CL2019000221A1 - Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. - Google Patents

Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.

Info

Publication number
CL2019000221A1
CL2019000221A1 CL2019000221A CL2019000221A CL2019000221A1 CL 2019000221 A1 CL2019000221 A1 CL 2019000221A1 CL 2019000221 A CL2019000221 A CL 2019000221A CL 2019000221 A CL2019000221 A CL 2019000221A CL 2019000221 A1 CL2019000221 A1 CL 2019000221A1
Authority
CL
Chile
Prior art keywords
thiazolo
substituted compounds
pyridine substituted
malt1 inhibitors
malt1
Prior art date
Application number
CL2019000221A
Other languages
English (en)
Inventor
Gagan Kukreja
Nageswara Rao Irlapati
Arun Rangnath Jagdale
Gokul Keruji Deshmukh
Vinod Popatrao Vyavahare
Kiran Chandrashekhar Kulkarni
Neelima Sinha
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CL2019000221A1 publication Critical patent/CL2019000221A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE FÓRMULA GENERAL (I), EN LA QUE R1-R3 SON COMO SE DEFINEN EN EL PRESENTE DOCUMENTO, PARA SU USO COMO INHIBIDORES DE MALT1 EN EL TRATAMIENTO DE ENFERMEDADES O TRASTORNOS AUTOINMUNES E INFLAMATORIOS. TAMBIÉN SE DESCRIBEN MÉTODOS PARA SINTETIZAR LOS COMPUESTOS. TAMBIÉN SE DESCRIBEN COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN UN COMPUESTO DE LA INVENCIÓN Y UN MÉTODO PARA TRATAR UN PACIENTE POR UNA ENFERMEDAD O TRASTORNO AUTOINMUNE O INFLAMATORIO, POR EJEMPLO, UN CÁNCER, ADMINISTRANDO UN COMPUESTO DE LA INVENCIÓN.
CL2019000221A 2016-07-29 2019-01-28 Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. CL2019000221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201621026107 2016-07-29

Publications (1)

Publication Number Publication Date
CL2019000221A1 true CL2019000221A1 (es) 2019-06-07

Family

ID=59745317

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000221A CL2019000221A1 (es) 2016-07-29 2019-01-28 Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.

Country Status (15)

Country Link
US (1) US20190275012A9 (es)
JP (1) JP2019522035A (es)
KR (1) KR20190033607A (es)
CN (1) CN110312724A (es)
AU (1) AU2017302182B2 (es)
CA (1) CA3032334A1 (es)
CL (1) CL2019000221A1 (es)
DO (1) DOP2019000020A (es)
IL (1) IL289474A (es)
MX (1) MX2019001132A (es)
PE (1) PE20190656A1 (es)
PH (1) PH12019500214A1 (es)
RU (1) RU2019104890A (es)
SG (1) SG11201900745VA (es)
WO (1) WO2018020474A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3592731A4 (en) * 2017-03-08 2020-10-07 Cornell University MALT1 INHIBITORS AND THEIR USES
CN111433198A (zh) * 2017-11-17 2020-07-17 合帕吉恩治疗公司 作为ask1的抑制剂的脲衍生物
KR20200105678A (ko) 2017-12-28 2020-09-08 더 제너럴 하스피탈 코포레이션 Cbm 시그날로좀 복합체 표적화는 조절 t 세포의 종양 미세환경에 대한 염증유발을 유도함
AU2019289223B2 (en) * 2018-06-18 2023-09-21 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
EA202190055A1 (ru) * 2018-06-18 2021-04-23 Янссен Фармацевтика Нв Производные пиразола в качестве ингибиторов malt1
CN109265453A (zh) * 2018-10-23 2019-01-25 华侨大学 一种用作caspase-3激活剂的缩氨基脲类衍生物及其应用
BR112021009994A2 (pt) * 2018-11-28 2021-08-17 Takeda Pharmaceutical Company Limited composto, e, medicamento
US12404260B2 (en) * 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
TW202115077A (zh) * 2019-07-01 2021-04-16 大陸商上海齊魯銳格醫藥研發有限公司 Ｍａｌｔ１抑制劑及其用途
WO2021063735A1 (en) * 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
IL294214B2 (en) * 2019-12-27 2026-04-01 Schrodinger Inc Cyclic compounds and methods of using same
EP4163280A4 (en) * 2020-05-27 2024-06-05 Takeda Pharmaceutical Company Limited METHOD FOR PRODUCING A HETEROCYCLIC COMPOUND
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
WO2022081967A1 (en) * 2020-10-16 2022-04-21 Rheos Medicines, Inc. Malt1 modulators and uses thereof
JP2023549835A (ja) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス，インコーポレーテッド がんを治療する材料及び方法
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
JP2025501056A (ja) 2021-12-30 2025-01-17 シャンハイ ハンソー バイオメディカル カンパニー リミテッド 三環系誘導体阻害剤、その製造方法と応用
CN116535424B (zh) * 2022-01-26 2025-04-11 武汉誉祥医药科技有限公司 作为malt1抑制剂的三并环化合物及其药物组合物和应用
KR20240144146A (ko) 2022-02-02 2024-10-02 오노 야꾸힝 고교 가부시키가이샤 Malt1 저해약을 유효 성분으로서 포함하는 암 치료제
CN119095837A (zh) 2022-02-03 2024-12-06 希四克斯探索有限公司 作为malt1抑制剂的杂环衍生物
US20250326738A1 (en) * 2022-03-31 2025-10-23 Rarefied Biosciences, Inc. MALT1 Modulators and Uses Thereof
TW202345806A (zh) * 2022-03-31 2023-12-01 美商艾伯維有限公司 噻唑并〔５，４－ｂ〕吡啶ｍａｌｔ－１抑制劑
WO2024116528A1 (ja) * 2022-11-28 2024-06-06 ユニマテック株式会社 含フッ素ピリドン化合物およびその製造方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP2003513909A (ja) * 1999-11-05 2003-04-15 ワーナー−ランバート・カンパニー Ａｃａｔ阻害剤によるプラーク破裂の予防
AU2003222667A1 (en) * 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
US9051595B2 (en) 2007-06-01 2015-06-09 University Of Lausanne Malt1 specific cleavage in assay and screening method
EP2222326B2 (en) 2007-11-21 2015-02-25 Vib Vzw Inhibitors of malt1 proteolytic activity and uses thereof
WO2013013816A1 (en) * 2011-07-26 2013-01-31 Grünenthal GmbH Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
JP6069321B2 (ja) * 2011-08-02 2017-02-01 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハーＨｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ Ｕｎｄ Ｕｍｗｅｌｔ Ｇｍｂｈ フェノチアジン誘導体によるｍａｌｔ１プロテアーゼの選択的阻害
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
EA201590916A1 (ru) 2012-11-09 2016-02-29 Корнэлл Юниверсити Низкомолекулярные ингибиторы malt1
WO2014086478A1 (en) 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
EP4001275B1 (en) 2013-06-26 2024-11-27 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH (s)-enantiomer of mepazine as paracaspase (malt1) inhibitor for the treatment of cancer
EP3097124B1 (en) 2014-01-21 2018-12-19 Helmholtz Zentrum München Means and methods for detecting activated malt1
JP6545197B2 (ja) * 2014-05-28 2019-07-17 ノバルティス アーゲー 新規なピラゾロピリミジン誘導体およびｍａｌｔ１阻害剤としてのその使用
DE102015210224A1 (de) 2015-06-02 2016-12-08 Universitätsklinikum Hamburg-Eppendorf Neuer wirkstoff zur behandlung von krebs
WO2017040304A1 (en) 2015-08-28 2017-03-09 Cornell University Malt1 inhibitors and uses thereof
WO2017057695A1 (ja) 2015-09-30 2017-04-06 東レ株式会社 ジフェニルピラゾール誘導体及びその医薬用途
EP3374361A1 (en) 2015-11-13 2018-09-19 Novartis AG Novel pyrazolo pyrimidine derivatives
EP3592731A4 (en) * 2017-03-08 2020-10-07 Cornell University MALT1 INHIBITORS AND THEIR USES

Also Published As

Publication number Publication date
JP2019522035A (ja) 2019-08-08
AU2017302182B2 (en) 2021-11-04
WO2018020474A1 (en) 2018-02-01
US20190160045A1 (en) 2019-05-30
SG11201900745VA (en) 2019-02-27
US20190275012A9 (en) 2019-09-12
PE20190656A1 (es) 2019-05-08
RU2019104890A (ru) 2020-08-31
CA3032334A1 (en) 2018-02-01
KR20190033607A (ko) 2019-03-29
MX2019001132A (es) 2019-12-16
DOP2019000020A (es) 2019-04-30
RU2019104890A3 (es) 2020-08-31
IL289474A (en) 2022-02-01
AU2017302182A1 (en) 2019-03-07
CN110312724A (zh) 2019-10-08
PH12019500214A1 (en) 2019-10-28

Similar Documents

Publication Publication Date Title
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CY1121850T1 (el) Διαρυλο μακροκυκλοι ως ρυθμιστες των πρωτεϊνικων kinασων
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2019000266A1 (es) Composición de cannabis.
UA124347C2 (uk) Циклічна динуклеотидна сполука
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
MX2019005465A (es) Metodo de tratamiento de un tumor inmunoterapeutico.
CO2017011484A2 (es) Inhibidores de bromodominio
MX2019009653A (es) Inhibidores de mnk sustituidos con piperidina y metodos relacionados con los mismos.
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CL2019002240A1 (es) Dendrímeros terapéuticos.
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
CY1122763T1 (el) Νεες ενωσεις ιμιδαζοπυριδαζινης και η χρηση αυτων
MX2018010028A (es) Derivados de carboxamida utiles como inhibidores de rsk.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
UY36758A (es) Inhibidores del potenciador del homólogo zeste 2
MX387726B (es) Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer.